Flubromazepam: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 27: | Line 27: | ||
}} |
}} |
||
'''Flubromazepam''' is the name used for a [[benzodiazepine]] derivative which was first made in 1960,<ref>US Patent 3136815 - Amino substituted benzophenone oximes and derivatives thereof</ref> but was never marketed and did not receive any further attention or study until it started to be sold as a [[research chemical]] in late 2012. Its closest relative is [[ |
'''Flubromazepam''' is the name used for a [[benzodiazepine]] derivative which was first made in 1960,<ref>US Patent 3136815 - Amino substituted benzophenone oximes and derivatives thereof</ref> but was never marketed and did not receive any further attention or study until it started to be sold as a [[research chemical]] in late 2012. Its closest relative is [[flunitrazepam]]. Replacing the 2'-Cl with a 2'-F is the single alteration. Flubromazepam is currently being studied.<ref>[http://www.uniklinik-freiburg.de/rechtsmedizin/live/forschung/Conferences/MoosmannTIAFT201301.pdf Moosmann B, et al. Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples. Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany]</ref> It presumably has [[sedative]], [[hypnotic]], [[muscle relaxant]], and [[antiepileptic]] effects common to all benzodiazepine derivatives. A closely related compound, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one,<ref>US Patent 5317018 - Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy</ref> also appears to have been sold under the same name. |
||
Its onset is around 4 hours and reaches its peak at 8 hours.{{Citation needed|date=September 2014}} |
Its onset is around 4 hours and reaches its peak at 8 hours.{{Citation needed|date=September 2014}} |
||
Revision as of 02:42, 1 January 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Elimination half-life | 106 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H10BrFN2O |
| Molar mass | 333.16 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Flubromazepam is the name used for a benzodiazepine derivative which was first made in 1960,[1] but was never marketed and did not receive any further attention or study until it started to be sold as a research chemical in late 2012. Its closest relative is flunitrazepam. Replacing the 2'-Cl with a 2'-F is the single alteration. Flubromazepam is currently being studied.[2] It presumably has sedative, hypnotic, muscle relaxant, and antiepileptic effects common to all benzodiazepine derivatives. A closely related compound, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one,[3] also appears to have been sold under the same name. Its onset is around 4 hours and reaches its peak at 8 hours.[citation needed]
See also
References
- ^ US Patent 3136815 - Amino substituted benzophenone oximes and derivatives thereof
- ^ Moosmann B, et al. Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples. Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany
- ^ US Patent 5317018 - Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy